Document:

EXHIBIT 10.2

 

AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT

 

This AMENDMENT
NO. 2 TO ASSET PURCHASE AGREEMENT (this “Second
Amendment”), dated as of March 25, 2009, is by and between OSIRIS THERAPEUTICS, INC., a Delaware corporation (“Seller”), and NUVASIVE,
INC., a Delaware corporation (“Purchaser”).  Capitalized terms used herein and not
otherwise defined shall have the meaning given them in that certain Asset
Purchase Agreement by and between Seller and Purchaser dated May 8, 2008,
as amended pursuant to that certain Amendment to Asset Purchase Agreement by
and between Seller and Purchaser dated September 30, 2008 (collectively,
the “Agreement”).  Seller and Purchaser shall each be referred
to herein as a “Party” and collectively as
the “Parties.”

 

WHEREAS, pursuant to Section 9.3 of the Agreement, the
Agreement may be amended by a written instrument signed by the parties to the
Agreement; and

 

NOW, THEREFORE, in consideration of the foregoing, the
agreements hereinafter set forth and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Parties agree
as follows:

 

1.                                       Amendments.

 

(a)                                   Section 1.1(a)(ii) of the
Agreement shall be deleted in its entirety.

 

(b)                                  Section 1.3 of the Agreement shall
be amended by deleting in its entirety the second sentence thereof and
inserting in its place the following:

 

“The consummation of the
Manufacturing Asset Transfer (the “Manufacturing Closing”) shall be held
on the fifteenth day following the execution by Purchaser and Seller of this
Second Amendment (the “Manufacturing Closing Date”) and at such time all
conditions to the Manufacturing Closing shall be deemed to have been waived or
satisfied.  In connection with the
Manufacturing Closing, either (a) the Purchaser shall assume that certain
Amended and Restated Tissue Procurement Processing and Supply Agreement by and
between Seller and AlloSource, dated February 1, 2008 (the “AlloSource
Supply Agreement”) or (b) the AlloSource Supply Agreement shall be amended,
modified, supplemented or terminated.”

 

(c)                                  Section 1.5(a) of the Agreement
shall be amended and restated in its entirety, as follows:

 

“(a)                            Milestones; Milestone
Payments.  From and after the
Technology Closing Date, in addition to the consideration set forth in Section 1.4
above, Purchaser shall, with respect to Sections 1.5(a)(i) and 1.5(a)(vi) below,
subject to, and contingent upon achievement of the post-Technology Closing
performance milestones of the Business set forth in Sections 1.5(a)(i) and
1.5(a)(vi) below, and, with respect to Sections 1.5(a)(ii), 1.5(a)(iii) and
1.5(a)(iv) below, on the dates set forth in Sections 1.5(a)(ii), 1.5(a)(iii) and
1.5(a)(iv) below (each, a “Milestone”) not later than the
applicable date for satisfaction of each Milestone set forth below (each a 

 

 

“Milestone
Expiration Date”), pay to Seller an amount of cash (in United States
dollars of immediately available funds) or common stock, par value $0.001 per
share, of Purchaser (“Purchaser Common Stock”) (the form of payment of
which is to be determined in the sole discretion of Purchaser), equal to the
First Milestone Payment, Second Milestone Payment, Third Milestone Payment,
Fourth Milestone Payment, Fifth Milestone Payment and/or Sixth Milestone
Payment, as applicable (the “Applicable Milestone Payment”) and each
Milestone shall be independent of each other Milestone and may be satisfied and
payment become due therefore regardless of non-satisfaction of any other
Milestone; provided, however, that (i) if Purchaser elects
to issue shares of Purchaser Common Stock in respect of any Applicable
Milestone Payment, then prior to such issuance and upon request by the
Purchaser, Seller shall deliver to Purchaser such representations and
warranties as Purchaser shall reasonably request for purposes of exempting the
issuance of such shares from the registration requirements of the Securities
Act, and (ii) if Purchaser elects to issue shares of Purchaser Common
Stock in respect of any Applicable Milestone Payment, the number of shares of
Purchaser Common Stock to be issued shall be equal to the Applicable Milestone
Payment divided by the Purchaser Common Stock Value.  The obligations of Purchaser under this Section 1.5(a) are
subject to the provisions of Section 1.5(c) below (regarding Purchaser’s
Rights of Set-Off).  For avoidance of
doubt, in no event shall the sum of all Applicable Milestone Payments made by
Purchaser to Seller under this Section 1.5 exceed Fifty Million Dollars
($50,000,000) (the “Maximum Milestone Amount.

 

(i)                                     If at any time following the Technology Closing Date
but at or prior to April 15, 2009, Seller shall have delivered to
Purchaser an aggregate of 75,000 cubic centimeters of Product (the “First
Delivery Threshold”) in accordance with the terms and provisions of, and subject
to the specifications set forth in, the Manufacturing Agreement, Purchaser
shall pay to Seller Five Million Dollars ($5,000,000) (the “First Milestone
Payment”).  The parties acknowledge
and agree that the First Milestone Payment was previously made by Purchaser and
that no further amount shall be due or owing with respect thereto.

 

(ii)                                  Purchaser shall pay to Seller Five Million Dollars
($5,000,000) on the date that Purchaser executes the Second Amendment (the “Second
Milestone Payment”).

 

(iii)                               Purchaser shall pay to Seller Twelve Million Five
Hundred Thousand Dollars ($12,500,000) on June 30, 2009 (the “Third
Milestone Payment”).

 

(iv)                              Purchaser shall pay to Seller Twelve Million Five
Hundred Thousand Dollars ($12,500,000) on September 30, 2009 (the “Fourth
Milestone Payment”).

 

(v)                                 [Intentionally
Omitted].

 

(vi)                              If at any time following the Technology Closing Date
the Business shall generate Thirty-Five Million Dollars ($35,000,000) in
cumulative Net Sales (the “Net Sales Threshold”), Purchaser shall pay to
Seller Fifteen Million Dollars ($15,000,000) (the “Sixth Milestone Payment”).

 

If any payment under this Section 1.5(a) is
made in the form of Purchaser Common Stock, then on the date of such payment
Purchaser shall provide to Seller (I) a certificate from a 

 

 

duly authorized officer of Purchaser certifying that
as of the date of such issuance (x) the Purchaser Common Stock so issued
has been duly authorized and is validly issued, fully-paid and non-assessable
and, (y) the provisions of Rule 144(c) of the Securities Act,
are satisfied and (II) a legal opinion from Purchaser’s legal counsel that
such Purchaser Common Stock has been duly authorized and validly issued, is
fully paid and non-assessable.  If
Purchaser is unable to satisfy the requirement set forth in the immediately
preceding sentence, Seller shall be under no obligation to accept Purchaser
Common Stock as payment for the Applicable Milestone Payment and Purchaser
shall make such Applicable Milestone Payment in the form of cash, in United
States dollars of immediately available funds.”

 

(d)                                 Sections 6.1 (a), (b),
and (d-i) of the Agreement shall be deleted in their entirety, and Seller
hereby specifically affirms that the representations and warranties in Section 6.1(c) thereof
are true and correct as of the date hereof.

 

(e)                                  Section 8.2(d) of
the Agreement shall be amended by adding at the end thereof the following
phrase “ ... and all liabilities associated with the assumption or termination of
the AlloSource Supply Agreement as contemplated by the Second Amendment.”

 

(f)                                     Section 9.13
of the Agreement shall be amended by deleting the definitions of “Allowable
Work in Process” and “WIP Value” in their entirety.  In addition, the Index of Defined Terms
contained in Section 9.13 shall be amended by eliminating the reference to
Work in Process contained therein.

 

2.                                       Columbia
Facility. 
Notwithstanding anything to the contrary in the Agreement (or any
exhibit or schedule to the Agreement), the Parties agree that Seller shall not
transfer, lease or sub-lease the 7015 Albert Einstein, Columbia Maryland
facility (the “Columbia Facility”) to
Purchaser, and Purchaser shall have no obligation to lease or sub-lease the
Columbia Facility.  The Parties agree
that (i) the Sublease Agreement by and between Broadwing Corporation and
Osiris, dated June 2, 2006 and the Agreement of Lease by and between
Columbia Gateway S-18, L.L.C. and Osiris, dated June 6, 2006 shall not be
Assumed Contracts (as defined in the Agreement) pursuant to the Agreement, and (ii) Schedule
1.1(a)(x) to the Agreement shall be amended to remove the Sublease
Agreement by and between Broadwing Corporation and Osiris, dated June 2,
2006 and the Agreement of Lease by and between Columbia Gateway S-18, L.L.C.
and Osiris, dated June 6, 2006  from such
Schedule 1.1(a)(x) to the Agreement. 
Purchaser agrees to timely dispose, at Purchaser’s cost, of all of the
assets at the Columbia Facility set forth on Exhibit A attached to this
Second Amendment.

 

3.                                       No Further
Amendment.  Except to
the extent expressly modified by this Amendment, all of the provisions of the
Agreement shall remain in full force and effect, without modification or
amendment and are ratified in all respects. 
This Amendment is limited by its terms and does not and shall not serve
to amend or waive any provision of the Agreement except as expressly provided
for in this Amendment.

 

4.                                       Governing Law;
General Provisions.  This
Amendment, including the validity hereof and the rights and obligations of the
parties hereunder, shall be construed, interpreted, enforced and governed by
and under the laws of the State of Delaware applicable to contracts

 

 

made and to be performed entirely in such
state, without regard to its rules regarding conflicts of law provisions.

 

5.                                       Counterparts,
Facsimile Execution.  This
Amendment may be executed in any number of counterparts, each of which shall
constitute an original but all of which shall constitute one and the same
instrument.  The Parties need not sign
the same counterpart.

 

[Signature Page to
Follow]

 

 

IN WITNESS WHEREOF, Seller and
Purchaser have each caused this Amendment No. 2 to Asset Purchase
Agreement to be executed by their respective duly authorized officers, all as
of the date first above written.

 

 

	
  SELLER:

  
	
   

  	
   

  
	
   

  	
  OSIRIS
  THERAPEUTICS, INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Richard W. Hunt

  
	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Richard
  W. Hunt

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
  Chief
  Financial Officer

  
	
   

  	
   

  	
   

  
	
   

  
	
  PURCHASER:

  
	
   

  	
   

  
	
   

  	
  NUVASIVE,
  INC.

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Jason Hannon

  
	
   

  	
   

  	
   

  
	
   

  	
  Name:

  	
  Jason
  Hannon

  
	
   

  	
   

  	
   

  
	
   

  	
  Title:

  	
  Senior
  Vice President, General Counsel and SecretaryEXHIBIT 10.3

 

SUPPLY AGREEMENT

 

This
SUPPLY AGREEMENT (this “Agreement”)
dated as of March 25, 2009, (“Effective Date”) is by and between OSIRIS THERAPEUTICS, INC., a Delaware corporation (“Osiris”),
and ALLOSOURCE, an Illinois not-for-profit
corporation (“AlloSource”) (any of which may be individually referred to herein
as a “Party” and collectively as the “Parties”).

 

RECITALS:

 

A.                                   Osiris is
engaged in the business of processing and manufacture of an osteobiologic
allograft material containing cancellous bone commonly known as Osteocel® and Osteocel Plus® (collectively, the “Product”) (the
development, manufacturing, marketing and sale of the Product shall be referred
to herein as the “Business”).

 

B.                                     Pursuant to
this Agreement, Osiris and AlloSource intend that Osiris supply to AlloSource
and that AlloSource will purchase certain of Osiris’s inventory, all on the
terms and conditions contained in, and as more fully set forth in, this
Agreement.

 

Section 1                                             Purchase;
No Liabilities.

 

(a)                                  Subject to the
terms and conditions set forth herein and simultaneously with the satisfaction
of the conditions set forth in clauses (i), below (the “Purchase Date”),
AlloSource agrees to purchase, and Osiris agrees to supply, free and clear of
all liens, all right, title and interest of Osiris in, to and under all Osiris’s
Product inventory which has been manufactured by Osiris in accordance with the
specifications, excluding any Product that has, as of the Manufacturing Closing
(defined below), failed any testing requirement or any quality test and
excluding any Product that should have been discarded based on information
available to Osiris prior to the Manufacturing Closing (the “Inventory”).  Notwithstanding the foregoing, the Inventory
is considered donated human tissue under quarantine for which donor eligibility
and product availability for distribution determinations are not completed,
prohibiting the product being transplanted until eligibility and availability
for distribution determinations are completed as defined in Title 21 Code of
Federal Regulations part 1271. The purchase of Inventory is subject to the
following:

 

(i)                                     Osiris and
NuVasive, Inc. shall complete both the “Technology Closing” and the “Manufacturing
Closing” (as defined in the Asset Purchase Agreement effective May 8, 2008
by and between Osiris and NuVasive, as amended (collectively the “APA”)),
within fifteen (15) days of the execution of this Agreement;

 

(b)                                 AlloSource and **** acknowledge
that the Amended and Restated Tissue Procurement and Processing and Supply
Agreement and dated as of February 1, 2008 by and 

 

****
Portions of this page have been omitted pursuant to a request for
Confidential Treatment filed separately with the Commission.

 

(continued...)

 

 

between
Osiris and AlloSource shall be: (a) assigned by Osiris to NuVasive in
connection with the Manufacturing Closing; and (b) amended, modified,
supplemented or terminated upon terms and conditions mutually satisfactory to
each of NuVasive and AlloSource.”

 

(c)                                  AlloSource
shall not assume by virtue of this Agreement or the transactions contemplated
hereby, and shall have no liability for, any liabilities of Osiris.

 

(d)                                 Except as
expressly specified herein, Osiris shall cease processing of any new donor
tissue and shall use best efforts to complete all processing of Inventory
within five (5) days of the Effective Date.

 

Section 2                                             Purchase Price.  The “Purchase
Price” shall be calculated by multiplying $**** times the number of
cubic centimeters of Inventory purchased hereunder;  Three business days prior to the Purchase
Date, Osiris shall provide AlloSource with an estimated listing and itemization
of the work in progress inventory, which is subject to inspection and
verification by AlloSource, such inspection and verification to occur upon reasonable
written notice by AlloSource to Osiris. 
AlloSource shall pay one third of the Purchase Price on each of: 45, 75,
and 90 days from the Manufacturing Closing. 
AlloSource and Osiris shall have
the independent and bilateral right to withhold and set-off against any amount
otherwise due to be paid (but not yet paid) to each other any amounts due from
the other Party, including with respect to the indemnity provided in Section 9.

 

Section 3                                             Osiris
Representations and Warranties.

 

(a)                                  The Inventory
shall (a) conform with the applicable specifications therefore and with
all promises, warranties or affirmations of fact set forth in regulatory
documents or made on the container or label for the Inventory; (b) have
been procured, processed, labeled, handled, packaged and shipped in accordance
with industry standards, the specifications, all necessary quality control
procedures and all applicable laws and regulations; and (c) not infringe
or misappropriate any patent or other intellectual property right of any third
party. There is no design or manufacturing defect with respect to the Inventory
other than defects found by AlloSource during its review and Release of the
Inventory.

 

(b)                                 All
documentation supplied to AlloSource in connection with the Inventory shall, to
the knowledge of the Osiris, be accurate and complete.

 

(c)                                  All permits
listed on Schedule 2.11 of the APA are in full force and effect.

 

(d)                                 Osiris is in
compliance in all material respects with all applicable laws, statutes,
regulations, rules, ordinances, standards, guidelines and judicial or
administrative orders issued

 

(...continued)

 

****
Portions of this page have been omitted pursuant to a request for
Confidential Treatment filed separately with the Commission.

 

2

 

by
the FDA or any other governmental agency or the American Association of Tissue
Banks, relating to the Inventory. To the extent appropriate for Inventory, all
Inventory has been processed, manufactured, packaged, labeled, stored, handled,
and distributed by Osiris in compliance with Osiris quality control standards
and all applicable laws including Good Tissue Practices and the United States
National Organ Transplant Act. None of the Inventory has been recalled or
subject to a field safety notification, and Osiris has not received written
notice (whether completed or pending) of any proceeding seeking recall,
suspension or seizure of the Inventory.

 

Section 4                                             Cooperation. Until all of the
Inventory is Released, Osiris will cooperate and assist AlloSource with the
Release thereof. Specifically, following the Manufacturing
Closing, AlloSource will be fully responsible for final Release of all
Inventory. Osiris will cooperate with AlloSource on the Release of  Inventory; for clarity Osiris will be closing
operations and will terminate most of its employees but hereby agrees to keep a
minimum of 4 employees for 6 weeks to cooperate with AlloSource. Osiris’
cooperation shall include obtaining any missing or required donor information from
recovery agencies, completing and correcting all processing records, completing
all quality control testing transferred to AlloSource and cooperating with
AlloSource on the planning and scheduling of the transfer of Inventory to
fulfill the obligations specified in Section 5. In the event that
AlloSource requests in writing, specific services beyond the initial six week
period, Osiris will agree to extend the employment period for such person(s) to
a mutually agreed to period of time and AlloSource will agree to reimburse
Osiris, at its cost, for the extension. Osiris’s failure to comply with this
covenant will result in the AlloSource’s withholding the final installment
payment of the Purchase Price until such time as Osiris provides the necessary
cooperation to effect a Release.  For purposes of this Agreement, “Release(d)”
means that AlloSource has received all information and documentation and other
cooperation described above from Osiris necessary for  AlloSource to determine that each item of
Inventory is acceptable or not acceptable for distribution to a third party for
human transplantation. In the event that AlloSource determines that Osiris is
not meeting the cooperation as defined in Section 4, AlloSource will
notify Lou Barnes (or other employees designated by Osiris) within three days
of determination of non-cooperation.

 

Section 5                                             Shipping; Transportation.   Within thirty (30) days of the Purchase Date,
the Inventory remaining in Osiris’ Columbia facility will be transferred to
AlloSource to shipping location(s) specified by AlloSource,  AlloSource shall be responsible, at
AlloSource’s cost, for the management, insurance, transportation costs, permits
and selection of carriers to transport the Transferred Assets.  Osiris will cooperate with AlloSource on the
planning and scheduling of the transfer(s).

 

Section 6                                             Records. Osiris shall
maintain accurate and complete records of its procurement, processing, supply,
and shipment of Inventory hereunder for the period of time required by
applicable laws or regulations.  Upon
reasonable prior written request of AlloSource, or whenever requested to comply
with laws or regulations, Osiris shall provide AlloSource with such
information, including documentation, requested by AlloSource regarding the
Inventory,

 

3

 

including,
without limitation, quality control and quality assurance of Inventory supplied
hereunder.

 

Section 7                                             Complaints;
Adverse Claims.  Osiris
shall provide written notification of any complaint or adverse claim related to
the Inventory as soon as reasonably practical after Osiris’s receipt of such
complaint or claim.  Each Party agrees to
provide reasonable assistance and cooperation to the other Party in the
investigation and resolution of any such complaint or claim related to the
Inventory, including any recall, field correction, market withdrawal, stock
recovery or other similar action; provided that AlloSource shall have final
authority and responsibility for all decisions concerning the Inventory and
responsibility for all communication with any non-governmental third party
related to Inventory.

 

Section 8                                             Insurance.  Osiris shall carry and maintain insurance
which shall be primary in nature and cover all risks and liability, including
without limitation general and products liability, associated with the
Inventory other than the acts and omission of AlloSource in releasing the
Inventory and with limits of liability equal to at least **** in the
aggregate per year.  Such insurance shall
be claims made based and shall include tail coverage under the same terms for a
period of at least ten (10) years following the Purchase Date.

 

Section 9                                             Indemnification.  Osiris hereby agrees to indemnify,
defend and save harmless AlloSource and its directors, officers, employees,
affiliates, agents, advisors, representatives, members and assigns
(collectively, the “AlloSource Indemnified Parties”) from, against and
in respect of any and all any loss, claim, tax, demand, loss, deficiency,
damage, liability, judgment, fine, penalty, fee, cost or expense (including,
without limitation, reasonable attorneys’, consultants’ and experts’ fees and
expenses) incurred, paid, accrued or sustained by the AlloSource Indemnified
Parties, including, without limitation, any costs of defending any action,
suit, claim, charge, cause of action or suit (whether in contract or tort or
otherwise), litigation (whether at law or in equity, whether civil or
criminal), controversy, assessment, arbitration, investigation, hearing, complaint,
demand or other proceeding to, from, by or before any arbitrator, court,
tribunal or other governmental entity or enforcing the AlloSource Indemnified
Party’s rights under this Agreement, incurred or suffered by any AlloSource
Indemnified Party arising out of, or related to, the following (each, a “AlloSource
Claim”):

 

(a)                                  any
misrepresentation or breach of warranty made by Osiris in this Agreement or in
any document, certificate or other instrument required to be delivered by
Osiris under this Agreement;

 

(b)                                 any breach or
non fulfillment by Osiris when required to be performed of any covenant or
agreement made or to be performed by Osiris in this Agreement or in any
agreement or instrument entered in connection with this Agreement;

 

****
Portions of this page have been omitted pursuant to a request for
Confidential Treatment filed separately with the Commission.

 

4

 

(c)                                  any fraud or
intentional misrepresentation with respect to, or intentional breach of, this
Agreement by Osiris; and

 

(d)                                 any liabilities
related to the Business, the Product, the Inventory or Osiris, whether arising
before, on or after the Manufacturing Closing, including any defect in the
Inventory or any personal injury caused by the Inventory, but excluding any act
or omission by  AlloSource in releasing
the Inventory. Furthermore, AlloSource affirms that Inventory as defined in Section 1(a) will
be Released by AlloSource and any deficiency in the Release process will void
Osiris’ Inventory indemnification.

 

Section 10                                      Miscellaneous.

 

(a)                                  Merger Clause.  This Agreement contain the
final, complete and exclusive statement of the agreement between the parties
with respect to the transactions contemplated herein.

 

(b)                                 Amendments.  No
amendment to, or any waiver with respect to any provision of, this Agreement
shall be effective unless in writing and executed by both parties.

 

(c)                                  Notices.  All
notices, requests and demands and other communications hereunder must be in
writing and shall be deemed to have been duly given (i) if given by
facsimile, when such facsimile is transmitted to the number specified in this
Agreement, if written confirmation of receipt thereof is obtained, (ii) on
the date of delivery shown on the return receipt (or, if none shown, three days
after deposit in the mail) if placed in the United States mails and forwarded
by registered or certified mail, return receipt requested, postage prepaid, or (iii) one
business day after deposit in the mail, if delivered, prepaid, to an overnight
courier.  All such communications shall be addressed as follows:

 

	
   

  	
  (i)

  	
  if to Osiris:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Osiris
  Therapeutics, Inc.

  
	
   

  	
   

  	
  7015
  Albert Einstein Avenue

  
	
   

  	
   

  	
  Columbia,
  Maryland 21046

  
	
   

  	
   

  	
  Attention: 
  Chief Financial Officer

  
	
   

  	
   

  	
  Facsimile:
  (443) 283-4259

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  with
  a required copy (which shall not constitute notice) to:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  McKenna Long & Aldridge LLP

  
	
   

  	
   

  	
  303
  Peachtree St., NE, Suite 5300

  
	
   

  	
   

  	
  Atlanta,
  Georgia 30308

  
	
   

  	
   

  	
  Attention: 
  Michael Cochran, Esq.

  
	
   

  	
   

  	
  Facsimile:
  (404) 527-4198

  
	
   

  	
   

  	
   

  
	
   

  	
  (ii)

  	
  if to AlloSource:

  

 

5

 

	
   

  	
   

  	
  AlloSource

  
	
   

  	
   

  	
  6278
  South Troy Circle

  
	
   

  	
   

  	
  Centennial,
  Colorado 80111

  
	
   

  	
   

  	
  Attention:
  Kevin J. Cmunt

  
	
   

  	
   

  	
  Facsimile:
  (720) 873-0212

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  with
  a required copy (which shall not constitute notice) to:

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
  Shipman & Goodwin LLP

  
	
   

  	
   

  	
  One
  Constitution Plaza

  
	
   

  	
   

  	
  Hartford,
  Connecticut 06103

  
	
   

  	
   

  	
  David
  M. Mack, Esq.

  
	
   

  	
   

  	
  Facsimile:
  (860) 251-5211

  

 

Any
party may change the address(es) to which notices to it are to be sent by
giving notice of such change to the other parties in accordance with this
Section.

 

(d)                                 Captions.  The
captions are for convenience of reference only and shall not be construed as a
part of this Agreement.

 

(e)                                  Governing Law.  This
Agreement shall be governed by and construed and enforced in accordance with
the laws of the State of Delaware without regard to its conflicts of law
principles.

 

(f)                                    Counterparts.  This
Agreement may be executed in any number of counterparts (including those
delivered by facsimile or other electronic means), each of which shall
constitute an original but all of which taken together shall constitute one and
the same instrument.  The parties need not sign the same counterpart.

 

(g)                                 Benefits and Binding Effect.  No party
may assign or transfer any of their respective rights, benefits or obligations
under this Agreement without the consent in writing of the other party hereto.

 

(h)                                 Simultaneously
Executed Contracts: This Agreement shall be effective when all of:
this Agreement, the 3rd Amendment to the NuVasive-Osiris Manufacturing
Agreement, the AlloSource-NuVasive Processing and Supply Agreement and the 2nd Amendment to the NuVasive-Osiris Asset
Purchase Agreement are fully executed.

 

[Signature Page to Follow]

 

6

 

IN WITNESS WHEREOF, the parties have each
caused this Supply Agreement to be executed by their respective duly authorized
officers, all as of the date first above written.

 

 

	
   

  	
  OSIRIS
  THERAPEUTICS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Richard W. Hunt

  
	
   

  	
  Name:

  	
  Richard
  W. Hunt

  
	
   

  	
  Title:

  	
  Chief
  Financial Officer

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  ALLOSOURCE

  
	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Thomas A. Cycyota

  
	
   

  	
  Name:

  	
  Thomas
  A. Cycyota

  
	
   

  	
  Title:

  	
  President
  and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]